Australia's CSL taps Amazon's cloud unit to boost research pipeline

Sept 29 (Reuters) - Australian ‌biotechnology firm ​CSL ​said on Tuesday it is collaborating with Amazon's cloud arm to harness ‌AI and cloud technology across its research ⁠and clinical development pipeline.

Here are some more details:

• The ‌partnership with Amazon Web ‌Services (AWS) will enable CSL's scientists to analyse complex scientific data and identify potential drug ​targets earlier in the discovery process, helping to accelerate research and shorten development timelines, ⁠the company said.

• On the clinical front, CSL said it ​will also use AWS's cloud and AI tools to reduce manual workloads in ​protocol drafting, data management, ‌and submission processes.

• The firm aims to link laboratory and computational work ⁠more closely, enabling experimental findings to inform research models and decisions faster.

• The partnership with Seattle-based ⁠AWS comes after US President Donald Trump announced a ​new round of drug-pricing agreements with international pharmaceutical companies, including CSL, in early September.

• In mid-August, CSL posted ‌better-than-expected annual underlying earnings and forecast growth in 2027 on the back ‌of its core plasma division.

• Shares of ⁠CSL were largely ‌unchanged at A$181.9, ​as of 0023 GMT.

(Reporting by Aamir Shaik Khalid in Bengaluru; Editing by Subhranshu ‌Sahu)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• US stock futures tick higher as tech steadies though oil, yields stay high
• AIxCrypto proposes $200M all-stock deal for Faraday Future robotics unit
• JPMorgan downgrades PepsiCo to Neutral in second cut of the week